A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Seagen Inc.
Seagen Inc.
Pliant Therapeutics, Inc.
Genentech, Inc.
National Cancer Institute (NCI)
Sotio Biotech Inc.
Rondo Therapeutics
Dragonfly Therapeutics
Merck Sharp & Dohme LLC
Dana-Farber Cancer Institute
Sutro Biopharma, Inc.
University of Miami
Tizona Therapeutics, Inc
University of Oklahoma
Institute of Cancer Research, United Kingdom
IDEAYA Biosciences
Eli Lilly and Company
Seagen Inc.
Novartis
Sairopa B.V.
Tempest Therapeutics
Bicara Therapeutics
Xencor, Inc.
Toray Industries, Inc
National University Hospital, Singapore
M.D. Anderson Cancer Center
Compugen Ltd
Turnstone Biologics, Corp.
Inspirna, Inc.
Washington University School of Medicine
Carisma Therapeutics Inc
Eli Lilly and Company
Vincerx Pharma, Inc.
Astellas Pharma Inc
Astellas Pharma Inc
Light Chain Bioscience - Novimmune SA
Gustave Roussy, Cancer Campus, Grand Paris
NGM Biopharmaceuticals, Inc
EDDC (Experimental Drug Development Centre), A*STAR Research Entities
Adlai Nortye Biopharma Co., Ltd.
ADC Therapeutics S.A.
Eli Lilly and Company
NGM Biopharmaceuticals, Inc
Celldex Therapeutics
Ikena Oncology
Stingthera, Inc.
Hefei TG ImmunoPharma Co., Ltd.
Atreca, Inc.
University of Florida